<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745744</url>
  </required_header>
  <id_info>
    <org_study_id>CeTMAd/ICC/2009</org_study_id>
    <secondary_id>2009-013554-32</secondary_id>
    <nct_id>NCT01745744</nct_id>
  </id_info>
  <brief_title>Application of Cell Regeneration Therapy With Mesenchymal Stem Cells From Adipose Tissue in Critical Chronic Ischemic Syndrome of Lower Limbs (CLI) in Nondiabetic Patients.</brief_title>
  <official_title>Clinical Trial Phase I / II, Multicentre, Open, Randomized Study of the Use of Mesenchymal Stem Cells From Adipose Tissue (CeTMAd) as Cell Regeneration Therapy in Critical Chronic Ischemic Syndrome of Lower Limb in Nondiabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Network for Design and Translation of Advanced Therapies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial phase I / II, prospective, multicenter, open, randomized, parallel-groups&#xD;
      controlled by two levels of dose to assess the safety and feasibility of the infusion of&#xD;
      mesenchymal stem cells from adipose tissue administered intra-arterially in nondiabetic&#xD;
      patients with chronic ischemia of lower limbs (CLI) and no possibility of revascularization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicenter, open, randomized, parallel-group controlled study for two levels&#xD;
      of dose.&#xD;
&#xD;
      The study population will consist of 30 non-diabetic patients with critical chronic ischemia&#xD;
      in at least one of the lower limbs (CLI) and without possibility of revascularization, from&#xD;
      whom results can clinically be evaluable, of whom, 20 patients will be included in the&#xD;
      experimental group (10 for each dose level) and 10 in the control group.&#xD;
&#xD;
      In each of the two dose levels to be used in the study, 15 patients will be included, who&#xD;
      will be randomized to the experimental group or the control group according to a distribution&#xD;
      2:1 (2 patients in the experimental group and 1 in control group), thus at each dose level,&#xD;
      we will have 10 patients in the experimental group (treated with mesenchymal cells of adipose&#xD;
      tissue) and 5 patients in the control group (conventional treatment, including the use of&#xD;
      prostaglandins per protocol).&#xD;
&#xD;
      Patients who are randomized to experimental treatment Group with CeTMAd may receive one of&#xD;
      the following dose levels:&#xD;
&#xD;
        -  0.5x106 cells / kg of patient weight&#xD;
&#xD;
        -  1x106 cells / kg of patient weight&#xD;
&#xD;
      The recruitment will be done with escalating doses, starting at the lower dose. To switch to&#xD;
      the higher dose will require a favorable opinion of the Ethics Committee of the H.&#xD;
      Universitario Virgen Macarena to evaluate the clinical status of patients and therapeutic&#xD;
      safety and study procedures.&#xD;
&#xD;
      Patients who are randomized to the treatment control group will continue with conventional&#xD;
      treatment which they were performing at the time of inclusion in the study (including the use&#xD;
      of prostaglandins as protocol).&#xD;
&#xD;
      STUDY OBJECTIVE: To evaluate the safety and feasibility of regenerative treatment with&#xD;
      mesenchymal stem cells from adipose tissue (CeTMAd), administered intraarterial in&#xD;
      nondiabetic patients with chronic critical ischemia of at least one lower limb without&#xD;
      possibilities of revascularization or alternative therapies. We will analyze the&#xD;
      complications from regenerative therapy and / or study procedures.&#xD;
&#xD;
        -  Main objectives:&#xD;
&#xD;
             1. Security: It will be studied the possible complications due to the procedure in the&#xD;
                first 24 hours of administration of CeTMAd, 1 month, 3 months, 6 months, 9 months&#xD;
                and 12 months.&#xD;
&#xD;
             2. Efficiency: It will be studied the generation of new vessels (vasculogenesis) and&#xD;
                enhancement of collateral circulation (angiogenesis / arteriogenesis).&#xD;
&#xD;
        -  Secondary objectives:&#xD;
&#xD;
      It will be studied the evolution of ankle brachial index, transcutaneous oxygen pressure,&#xD;
      degree of Rutherford-Becker, ulcer size, calf perimeter, the score of pain and intermittent&#xD;
      claudication (walking test).&#xD;
&#xD;
      Duration of the clinical trial: From the infusion to the patient of the Mesenchymal Stem&#xD;
      Cells from Adipose Tissue to the end of the monitoring, there will be 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events and serious adverse events</measure>
    <time_frame>12 months.</time_frame>
    <description>Number of adverse events and serious adverse events: 24h administration of CeTMAd, 1 month, 3 months, 6 months, 9 months and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of chronic critical ischemia</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months and 12 months</time_frame>
    <description>Parameters:Ankle brachial index, transcutaneous oxygen pressure, degree of Rutherford-Becker, larger ulcer size (as Texas classification), twin perimeter, score of pain and intermittent claudication (walking test).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mesenchymal stem cells from adipose tissue</intervention_name>
    <description>- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both sexes aged ≥ 18 and ≤ 89 years.&#xD;
&#xD;
          -  Nondiabetic.&#xD;
&#xD;
          -  Infrapopliteal atherosclerotic vascular disease of severe grade with either severe&#xD;
             claudication or Rutherford-Becker grade II-III-IV, of at least one lower limb. It is&#xD;
             defined critical ischemia of the lower limb as persistent/recurrent pain requiring&#xD;
             analgesia and / or non-healing present ulcers &gt; 4 weeks, with no evidence of&#xD;
             improvement with conventional therapies and / or walking test (stress test) between&#xD;
             1-6 minutes in two exercise tests separated by at least 2 weeks and / or&#xD;
             ankle-brachial index at rest &lt;0.8.&#xD;
&#xD;
          -  Inability of surgical or endovascular revascularization as recommended by the&#xD;
             TransAtlantic InterSociety Consensus (TASC).&#xD;
&#xD;
          -  Failure in the revascularization surgery performed at least 30 days before, with&#xD;
             persistence or entry in critical ischemia phase.&#xD;
&#xD;
          -  Life expectancy&gt; 2 years.&#xD;
&#xD;
          -  Not expected major amputation in the limb to treat in the next 12 months after&#xD;
             inclusion.&#xD;
&#xD;
          -  Normal biochemical parameters defined by:&#xD;
&#xD;
               1. Leukocytes ≥ 3000&#xD;
&#xD;
               2. Neutrophils ≥ 1500&#xD;
&#xD;
               3. Platelets ≥ 100,000&#xD;
&#xD;
               4. Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) ≤ 2.5 standard&#xD;
                  range institution&#xD;
&#xD;
               5. Creatinine ≤ 2.5 mg / dl.&#xD;
&#xD;
          -  Patients give their written informed consent to participate in the study.&#xD;
&#xD;
          -  Women of childbearing potential must have negative results on a pregnancy test done at&#xD;
             the time of inclusion in the study and agree to use a medically approved method of&#xD;
             contraception for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of malignancy or hematologic disease (myeloproliferative disease,&#xD;
             myelodysplastic syndrome or leukemia) in the last two years.&#xD;
&#xD;
          -  Patients with uncontrolled hypertension (defined as blood pressure&gt; 180/110 on more&#xD;
             than one occasion).&#xD;
&#xD;
          -  Severe heart failure (New York Heart Association class IV) or ejection fraction of the&#xD;
             left ventricle less than 30%.&#xD;
&#xD;
          -  Patients with malignant ventricular arrhythmias or unstable angina at the time of&#xD;
             infusion.&#xD;
&#xD;
          -  Diagnosis of deep vein thrombosis in the previous 3 months.&#xD;
&#xD;
          -  Active infection or wet gangrene at day of infusion of Mesenchymal Stem Cells from&#xD;
             Adipose Tissue.&#xD;
&#xD;
          -  Concomitant therapy including hyperbaric oxygen. It is allowed the use of antiplatelet&#xD;
             agents.&#xD;
&#xD;
          -  Body mass index&gt;40 kg/m2.&#xD;
&#xD;
          -  Patients with a diagnosis of alcoholism at the time of inclusion.&#xD;
&#xD;
          -  Untreated proliferative retinopathy.&#xD;
&#xD;
          -  Concomitant disease that reduces life expectancy to less than a year.&#xD;
&#xD;
          -  Predicted impossibility to obtain a biopsy providing 10 g of adipose tissue.&#xD;
&#xD;
          -  human immunodeficiency virus, hepatitis B virus or hepatitis C virus.&#xD;
&#xD;
          -  Difficulty in monitoring.&#xD;
&#xD;
          -  Stroke or myocardial infarction within the last 3 months.&#xD;
&#xD;
          -  Anemia (hemoglobin &lt;7.9 mg / dl).&#xD;
&#xD;
          -  Leukopenia.&#xD;
&#xD;
          -  Thrombocytopenia (&lt;100,000 platelets / ul).&#xD;
&#xD;
          -  Pregnant women or women of childbearing age who do not have adequate contraception.&#xD;
&#xD;
          -  Patients who participated in a clinical trial within the last 3 months prior to&#xD;
             inclusion in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael J. Ruiz-Salmerón</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hemodynamics Unit. Hospital Universitario Virgen Macarena.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio de la Cuesta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chronic Critical Ischemia Unit. San Lazaro Hospital.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San Lazaro</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.juntadeandalucia.es/terapiasavanzadas/</url>
    <description>Andalusian Initiative for Advanced Therapies</description>
  </link>
  <link>
    <url>http://www.cabimer.es</url>
    <description>Andalusian Molecular Biology and Regenerative Medicine Centre</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

